Trial Profile
Use of Maraviroc (MVC) in Immunological Non-Responder HIV-1-Infected Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Therapeutic Use
- 08 Mar 2012 Results presented at the 19th Conference on Retroviruses and Opportunistic Infections.
- 15 Oct 2011 Results presented at the 13th European AIDS Conference.
- 05 Aug 2011 Status changed from active, no longer recruiting to completed.